Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunoglobulin heavy variable 3-64 (IGHV3-64)
- Target
- IGHV3-64
- Molecular classification
- Immunoglobulin variable region, Immunoglobulin gene segment, Antibody component, Other
01
Overview
Immunoglobulin heavy variable 3-64 (IGHV3-64) encodes a variable region of the immunoglobulin heavy chain, which contributes to the antigen-binding site of antibodies. Each immunoglobulin molecule contains two identical heavy chains, and its variable domains, encoded by IGHV, IGHD, and IGHJ gene segments, are generated through V(D)J recombination in B-cells. This variable domain is crucial for the diversity and specificity of antibody-mediated immune responses. IGHV3-64 is one member of a large family of variable region gene segments, and its genetic diversity supports the adaptive immune system's ability to recognize a vast array of antigens[2][3][4][6].
- Other names
- IGHV3-64VHImmunoglobulin heavy variable 3-64IGHV364Immunoglobulin heavy chain variable region
02
Mechanism of action
None. Therapeutic antibodies may use this or similar variable regions for antigen recognition, but IGHV3-64 itself is not a direct mechanism-of-action target.
03
Biological functions
Antigen bindingImmune responseHumoral immunityGeneration of antibody diversity
04
Disease associations
Genetic polymorphisms and allelic variations in IGHV genes like IGHV3-64 have been linked to individual differences in immune responses and susceptibility to infection or autoimmunity. No direct disease linkage is established for this segment, but variable region usage can affect disease progression and immune function.
05
Safety considerations
None specific to IGHV3-64.
06
Interacting drugs
None. IGHV3-64 is not itself a direct drug target; no drugs interact with this gene segment.
07
Biomarkers
IGHV usage can be assessed in B-cell clonality studies, minimal residual disease tracking in hematological malignancies, and immune repertoire profiling, but IGHV3-64 is not a standard clinical biomarker on its own.
Beyond the preview
Go deeper on Immunoglobulin heavy variable 3-64 (IGHV3-64).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Immunoglobulin heavy variable 3-64 (IGHV3-64).